TY  -  JOUR
AU  -  Yu, Hu
AU  -  Di, Yu
AU  -  Jiahuan, Li
AU  -  Qiusi, Li
AU  -  Zhiwu, Li
AU  -  Zongyu, Zhang
AU  -  Changhui, Liu
AU  -  Hongfeng, Yan
T1  -  Study on independent influencing factors of compliance in patients with schizophrenia treated with paliperidone palmitate injection
PY  -  2026
Y1  -  2026-03-01
JO  -  Rivista di Psichiatria
JA  -  Riv Psichiatr
VL  -  61
IS  -  02
SP  -  78
EP  -  82
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-2502
Y2  -  2026/04/26
N2  -  Summary. Introduction. Patients with schizophrenia require long-term treatment, and poor medication compliance during therapy is a common issue. Poor compliance can lead to recurrent fluctuations in the patients’ disease course, exacerbate its progressive deterioration, severely impact patients’ social functioning and quality of life, and thus represents an increasingly serious public health problem. Long-acting injectable antipsychotics (LAIs) are generally considered one of the most effective treatments in psychiatry, which can reduce the substantial economic burden on patients and society, lowering readmission rates, improving patients’ quality of life, and decreasing healthcare costs. This study is a retrospective analysis based on follow-up data from patients with severe mental disorders. Objective. The study aims to explore the factors influencing medication compliance in schizophrenia patients treated with paliperidone palmitate injection, providing a basis for developing targeted compliance intervention strategies in clinical practice. The study included schizophrenia patients receiving paliperidone palmitate injection and systematically analyzed the impact of variables such as demographic characteristics, caregiver competence, social functioning, disease duration, and the presence of comorbid chronic conditions on medication compliance. Conclusions. Medication compliance in patients with schizophrenia is influenced by the interaction of multiple factors. Among these, age ≥50 years is a core independent risk factor affecting medication compliance, while having a guardian with good caregiving ability serves as an independent protective factor. The impact of a disease duration ≥10 years on compliance approaches statistical significance (p=0.050). A comparison of social functioning across the dimensions of the SDSS revealed that differences in social functioning deficits between the two groups with different levels of medication compliance were only evident in the dimensions of social withdrawal and interest in and concern for the external environment. This suggests that deficits in these specific dimensions of social functioning are also important factors influencing medication compliance in patients.
ER  -